Código QR (código de barras bidimensional)

Exposure–Response Analysis of Repotrectinib to Support the Dose Recommendation for Patients With ROS1‐Positive NSCLC or NTRK‐Positive Solid Tumors

ABSTRACT To support the benefit–risk assessment and dose justification of repotrectinib for patients with c‐ros oncogene 1 (ROS1) positive non‐small cell lung cancer (NSCLC) or neurotrophin receptor tyrosine kinase (NTRK)‐positive solid tumors, exposure–response analyses were conducted. The analysis...

ver descrição completa

Na minha lista:
Principais autores: Shengnan Du, Zheyi Hu, Jun Shen, Li Zhu, Amit Roy, Justine Lam, Ming Lu, Anna Kondic, Lora Hamuro
Formato: Artigo
Idioma:Inglês
Publicado em: Wiley 2025-12-01
coleção:CPT: Pharmacometrics & Systems Pharmacology
Assuntos:
advanced solid tumors
ALK
NSCLC
NTRK
repotrectinib
ROS1
Acesso em linha:https://doi.org/10.1002/psp4.70102
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados